- Home
- ONCY vs FBRX Comparison
ONCY vs FBRX Comparison
Compare ONCY & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- FBRX
- Stock Information
- Founded
- ONCY 1998
- FBRX N/A
- Country
- ONCY Canada
- FBRX United States
- Employees
- ONCY N/A
- FBRX N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONCY Health Care
- FBRX Health Care
- Exchange
- ONCY Nasdaq
- FBRX Nasdaq
- Market Cap
- ONCY 49.1M
- FBRX 44.8M
- IPO Year
- ONCY 1999
- FBRX N/A
- Fundamental
- Price
- ONCY $0.34
- FBRX $8.33
- Analyst Decision
- ONCY Strong Buy
- FBRX Strong Buy
- Analyst Count
- ONCY 4
- FBRX 3
- Target Price
- ONCY $4.33
- FBRX $80.50
- AVG Volume (30 Days)
- ONCY 820.6K
- FBRX 71.6K
- Earning Date
- ONCY 05-14-2025
- FBRX 05-15-2025
- Dividend Yield
- ONCY N/A
- FBRX N/A
- EPS Growth
- ONCY N/A
- FBRX N/A
- EPS
- ONCY N/A
- FBRX N/A
- Revenue
- ONCY N/A
- FBRX N/A
- Revenue This Year
- ONCY N/A
- FBRX N/A
- Revenue Next Year
- ONCY N/A
- FBRX N/A
- P/E Ratio
- ONCY N/A
- FBRX N/A
- Revenue Growth
- ONCY N/A
- FBRX N/A
- 52 Week Low
- ONCY $0.34
- FBRX $4.11
- 52 Week High
- ONCY $1.53
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- ONCY 24.92
- FBRX 53.25
- Support Level
- ONCY $0.34
- FBRX $8.25
- Resistance Level
- ONCY $0.45
- FBRX $13.84
- Average True Range (ATR)
- ONCY 0.04
- FBRX 1.31
- MACD
- ONCY -0.01
- FBRX 0.11
- Stochastic Oscillator
- ONCY 2.50
- FBRX 26.48
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).